| 40.03 -0.17 (-0.42%) | 09-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 49.12 | 1-year : | 57.37 |
| Resists | First : | 42.06 | Second : | 49.12 |
| Pivot price | 40.32  |
|||
| Supports | First : | 38.17 | Second : | 35.77 |
| MAs | MA(5) : | 40.11  |
MA(20) : | 40.34 |
| MA(100) : | 35.26 |
MA(250) : | 26.26 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 40.2 |
D(3) : | 37 |
| RSI | RSI(14): 50.9 |
|||
| 52-week | High : | 42.06 | Low : | 15.25 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CALT ] has closed above bottom band by 34.3%. Bollinger Bands are 69.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 63 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 40.85 - 41.01 | 41.01 - 41.15 |
| Low: | 39.12 - 39.31 | 39.31 - 39.48 |
| Close: | 39.69 - 40.01 | 40.01 - 40.29 |
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.
Mon, 16 Sep 2024
Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm - StockTitan
Fri, 13 Sep 2024
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Short Interest Down 60.7% in August - MarketBeat
Tue, 03 Sep 2024
Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei - StockTitan
Tue, 03 Sep 2024
Notice of extraordinary meeting of Calliditas Therapeutics AB (publ) - StockTitan
Wed, 31 Jul 2024
Number of shares and votes in Calliditas Therapeutics - StockTitan
Fri, 26 Jul 2024
Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis - StockTitan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 27 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 3.8 (%) |
| Held by Institutions | 0.3 (%) |
| Shares Short | 3 (K) |
| Shares Short P.Month | 6 (K) |
| EPS | -1.73 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.98 |
| Profit Margin | -30 % |
| Operating Margin | -5.7 % |
| Return on Assets (ttm) | -13.4 % |
| Return on Equity (ttm) | -157.2 % |
| Qtrly Rev. Growth | 107.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 59.21 |
| EBITDA (p.s.) | -13.53 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -245 (M) |
| Levered Free Cash Flow | -211 (M) |
| PE Ratio | -23.28 |
| PEG Ratio | 0 |
| Price to Book value | 20.21 |
| Price to Sales | 0.67 |
| Price to Cash Flow | -4.42 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|